Last month, Sonoma reached a significant milestone – our 5th anniversary! Hear from our very first employee, Joshua Beilke, on our incredible 5 years and the values that drive us forward as we work to develop engineered #Treg therapies for #autoimmune diseases. Learn more about our #OneSonoma values: https://bit.ly/4e7YAxk
Sonoma Biotherapeutics
生物技术研究
South San Francisco，California 14,599 位关注者
Leading the Next Frontier of Cell Therapy
关于我们
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.
- 网站
-
https://www.sonomabio.com
Sonoma Biotherapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- South San Francisco，California
- 类型
- 私人持股
- 领域
- cell therapy和autoimmune disease
地点
Sonoma Biotherapeutics员工
动态
-
Sonoma was onsite at the American College of Rheumatology (ACR) Convergence 2024 to connect with medical professionals, including clinical investigators from our REGULATE-RA Trial, to discuss our work in #rheumatoidarthritis and other #autoimmune diseases. Learn more about Learn more about Sonoma’s pipeline here: https://bit.ly/40BxU3U #ACR24?
-
-
We're #hiring in Seattle! Interested in joining our team of innovators dedicated to developing #Treg therapies for patients with #autoimmune diseases? Check out our open roles here: https://bit.ly/3ScM4CN
-
-
It was great to see our Sonoma teams in SSF and Seattle get into the Halloween spirit. We had a fang-tastic time watching ????'?? ?????? ?????????? ??????????????, ?????????????? ??????????, devouring wickedly delicious food, and sinking our teeth into delightful treats. Congrats to all our costume contest winners!
-
-
We are excited to announce that Sonoma CEO and Co-Founder,?Jeffrey Bluestone, was selected from candidates across multiple industries as one the Most Exceptional Entrepreneurs of 2024, and will be honored at the Goldman Sachs Builders and Innovators Summit in California this week. #GSInnovators
-
-
At Sonoma, we believe that the strength and success of our company is only possible by fostering a work environment where everyone feels confident to express themselves freely and authentically.? This #GlobalDiversityAwarenessMonth, and year-round, we are committed to diversity, equity and ensuring that individuals feel valued for their unique contributions. #OneSonoma Learn more about our values: https://bit.ly/4e7YAxk
-
-
We are excited to have Mei-Lun Wang, MD join the Sonoma team as SVP of Clinical Development. Dr. Wang’s passion for developing novel therapies and her expertise in immunology and gastroenterology will make her an impactful leader here at Sonoma. Welcome, Mei-Lun Wang, MD!
-
-
This morning, Sonoma CEO & President Jeffrey Bluestone participated on a panel discussing the advancement of cell therapies for autoimmune disease at the Goldman Sachs Research Cell Therapy Day in New York City. Learn more about Sonoma’s approach to treating these diseases: https://bit.ly/3TNmN3J
-
-
Tomorrow, Sonoma CEO & President Jeffrey Bluestone and CFO Jessica Stitt will attend the Bank of America Healthcare Trailblazers Private Company Conference in Boston, where Jeff will discuss the role of cell therapies in autoimmune disease during a panel discussion at the World Innovation Medical Forum. Learn more about the forum: https://bit.ly/47EfCkf
-
-
Our?CEO?Jeffrey Bluestone, recently sat down for a conversation with The Cura Foundation, to explore the intricacies of the immune system and?advancements in #immunology that have paved the way for Sonoma Bio's work to develop #Treg therapies with the potential to induce #immunetolerance and treat #autoimmune diseases Read the full interview here: https://lnkd.in/du9Dnggf.